2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.18. Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer

P1.18. Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer - 2

Back to course

Pdf Summary

This study examined the prevalence and genomic landscape of fibroblast growth factor receptor (FGFR) alterations in metastatic non-small cell lung cancer (mNSCLC), including patients who had received epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) treatment. The researchers analyzed de-identified records of patients who were sequenced using the Tempus xT assay. <br /><br />The study found that FGFR alterations were present in both treatment-naive and EGFR TKI-treated patients. The prevalence of FGFR alterations was around 13-14% in both groups. Copy number losses were the predominant type of FGFR alteration, accounting for 85% in treatment-naive patients and 93% in EGFR TKI-treated patients. The TACC3-FGFR3 fusion pair was detected in a small number of patients in both groups.<br /><br />FGFR2 and FGFR3 alterations were the most common FGFR alterations in both treatment-naive and EGFR TKI-treated patients. Additionally, the analysis identified novel FGFR fusions.<br /><br />The findings suggest that FGFR alterations may be a potential therapeutic target in mNSCLC, particularly in cases of EGFR TKI resistance. Further research is needed to determine if targeting FGFR alterations can provide therapeutic benefits.<br /><br />The study provides important insights into the prevalence and genomic landscape of FGFR alterations in mNSCLC. Understanding these alterations is critical for developing targeted therapies and improving treatment outcomes for patients with EGFR TKI resistance.

Asset Subtitle

Jacqueline Aredo, Stanford Cancer Institute, United States

Meta Tag

Speaker Jacqueline Aredo, Stanford Cancer Institute, United States

Topic Poster Listing

Keywords

fibroblast growth factor receptor alterations

metastatic non-small cell lung cancer

epidermal growth factor receptor tyrosine kinase inhibitor

Tempus xT assay

treatment-naive patients

EGFR TKI-treated patients

copy number losses

TACC3-FGFR3 fusion pair

FGFR2 alterations

FGFR3 alterations